78
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn’s disease

, , , , , , , , & show all
Pages 879-885 | Published online: 21 May 2018

Abstract

Background

Patients with newly diagnosed Crohn’s disease (CD) are associated with impaired physical and psychological well-being. These psychological characteristics are dynamic with the course of disease and could be influenced by medical treatment. Infliximab is effective and widely used in moderate-to-severe CD patients. The aim of this study was to evaluate the improvement of psychological status after infliximab treatment in patients with newly diagnosed CD.

Methods

Newly diagnosed moderate-to-severe CD patients were prospectively enrolled in our study. Infliximab 5 mg/kg was administered at weeks 0, 2, 6, 14, 22, and 30. Outcomes including disease severity, illness perceptions, coping strategies, anxiety, depression, and quality of life (QoL) were measured at baseline, week 14, and week 30.

Results

Eighty-two patients completed our study. The rates of clinical remission at weeks 14 and 30 were 59/82 (72.0%) and 58/82 (70.7%), respectively. Patients who achieved clinical remission at weeks 14 and 30 significantly improved in illness perceptions (P<0.001 and <0.001), maladaptive coping (P=0.005 and 0.004), anxiety (P<0.001 and <0.001), depression (P=0.004 and 0.004), and QoL (P<0.001 and <0.001). However, emotion-focused coping and problem-focused coping remained unchanged. For infliximab nonresponders, no significant changes were seen in illness perceptions, coping strategies, anxiety, depression, or QoL at week 14 or 30.

Conclusion

Effective infliximab treatment not only led to clinical remission in patients with newly diagnosed moderate-to-severe CD but also improved their psychological status including illness perceptions, maladaptive coping, anxiety, depression, and QoL.

Introduction

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by discontinuous inflammation that can occur anywhere in gastrointestinal tract, predominantly in the small intestine and the colon. As a chronic disease, CD brings physical, psychological, and social impairments to patients, which would pose negative effects on their lives in all aspects.Citation1Citation3 It is reported that quality of life (QoL) is reduced in CD patients compared to healthy controls.Citation4,Citation5 Moreover, high levels of anxiety and depression are inconvenient truths in CD patients.Citation6

It has been shown that psychological distress and QoL are not only associated with the disease severity itself but also associated with factors such as illness perceptions and coping strategies, which is supported by the Common Sense Model (CSM).Citation7 Illness perceptions are individual’s mental representations of their disease, while coping strategies are defined as the ways that an individual manages or deals with stress.Citation8 According to the CSM, patients generate cognitive representations based on the disease threat they are faced with. Patients would form illness perceptions in response to disease severity, which in turn may influence coping strategies and finally the illness outcomes such as psychological health and QoL.Citation9,Citation10 Therefore, disease severity, illness perceptions, coping strategies, psychological well-being, and QoL are significantly associated with each other.Citation8,Citation11,Citation12

For newly diagnosed CD patients, a complex psychological adaption occurs in a very short time, including emotional responses such as distress and guilt and behavioral responses such as seeking social support, taking new medication, and evaluating the disease’s impact on life. This adaption is dynamic with the unpredictable changes of disease progression since patients may experience ongoing physical and psychological challenges.Citation13

The treatment target for CD patients is to induce and maintain long-term remission. As a proinflammatory cytokine, tumor necrosis factor-α (TNF-α) plays an important role in the pathogenesis of CD. Infliximab is the human-murine chimera anti-TNF-α monoclonal antibody, which can bind to TNF-α with high affinity and neutralize its biological activity. Therefore, infliximab tends to alleviate patient’s symptoms quickly due to its prompt anti-inflammatory effect. Moreover, infliximab is by now the only anti-TNF-α agent available for us which is approved by China Food and Drug Administration (CFDA) for CD.Citation14,Citation15

Up till now, there are many cross-sectional studies on psychological well-being in CD patients, but it lacks prospective follow-up studies. Besides, most research focuses on remission rates after infliximab administration, while improvement of psychological status remains little known. This study was aimed to evaluate the changes of illness perceptions, coping strategies, psychological well-being (anxiety and depression), and QoL in patients with newly diagnosed CD after infliximab induction therapy.

Patients and methods

Patients

Newly diagnosed CD patients in Ruijin Hospital from September 1, 2014 to December 31, 2016 were prospectively enrolled. Inclusion criteria were as follows: 1) having Harvey–Bradshaw Index (HBI)Citation16,Citation17 score >4; 2) receiving infliximab as induction therapy; and 3) willing to answer the questionnaires at baseline, week 14, and week 30 after intervention independently and voluntarily. Exclusion criteria were as follows: 1) used CD-related medication before; 2) with contraindications of infliximab such as infection and stricture; 3) history of mental disease or psychological intervention before; and 4) with other chronic diseases.

This study was approved by the Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and written informed consent was signed by each patient.

Methods

At baseline, disease severity was measured using HBI, and patients were asked to fill a questionnaire measuring psychological characteristics. Then, a dose of 5 mg/kg intravenous infusion with infliximab was applied at weeks 0, 2, 6, 14, 22, and 30. The disease activity was re-evaluated at weeks 14 and 30. Clinical remission was defined as a HBI score of ≤4. Meanwhile, patients were asked to fill out the same questionnaires. All the questionnaires were completed in our hospital, and patients were encouraged to finish the questionnaires within 30 minutes.

Questionnaires

Illness perceptions

The Brief Illness Perceptions QuestionnaireCitation18 is a validated 9-item scale evaluating patient’s perceptions of overall effect of the disease, including consequences, timeline, personal control, treatment control, identity, concern, understanding, and emotional response. These items are scored on a continuous 0–10 scale, with higher total scores representing poorer illness perceptions.

Coping strategies

The Brief Coping Operations Preference EnquiryCitation19 is a validated 28-item questionnaire to assess coping behaviors, which are divided into adaptive problem-focused coping (active coping, planning, and using instrumental support), adaptive emotion-focused coping (positive reframing, acceptance, humor, religion, and using emotional support), and maladaptive coping (self-distraction, denial, venting, substance use, behavioral disengagement, and self-blame).Citation20 Each item is measured with a scale ranging from 0 to 3, with higher scores indicating that particular coping strategies are more adopted.

Anxiety and depression

The Hospital Anxiety and Depression Scale (HADS)Citation21 is a 14-item tool (seven items for a separate anxiety score and seven items for a separate depression score) to measure individual’s emotional adjustment. Each item is assessed on a 4-point scale. Total scores of either anxiety or depression range from 0 to 21, higher scores representing higher levels of anxiety or depression.

QoL

The Inflammatory Bowel Disease QuestionnaireCitation22 is a disease-specific, health-related QoL questionnaire, containing 32 items, with a graded response range of 1–7 and a total score range of 32–224, with lower scores indicating poorer QoL.

Statistical analysis

The paired t-test was used to calculate changes in the questionnaire measures from baseline to week 14 and from baseline to week 30 after treatment. Statistical significance was considered if the calculated two-tailed P-value was <0.05. SPSS 21.0 was used to perform all the data analyses.

Results

A flow diagram of our study is shown in . We found that of the 98 participants who met our inclusion criteria and filled out our baseline questionnaires, 87 patients completed questionnaires at week 14. Four patients experienced severe side effects to infliximab (two for allergy and the other two for myelosuppression) that treatment had to be terminated. Seven patients did not return the follow-up questionnaires. At week 30, 82 patients completed our questionnaires. One patient dropped out because of myelosuppression, and four patients did not complete follow-up assessment. Finally, 82 patients finished our study. The demographic characteristics of the final cohort are shown in .

Figure 1 Participant flow diagram.

Figure 1 Participant flow diagram.

Table 1 Demographics of participants

Fifty-nine of the 82 (72.0%) patients achieved clinical remission at week 14, with HBI decreasing from 6.24±1.68 to 2.42±1.00 (P<0.001). Changes in psychological parameters of these patients are shown in . Patients made significant improvement in illness perceptions (P<0.001), maladaptive coping (P=0.005), anxiety (P<0.001), depression (P=0.004), and QoL (P<0.001). At week 30, 58/82 (70.7%) patients were in clinical remission, whose HBI decreased from 6.40±1.70 to 2.26±1.12 (P<0.001). As shown in , patients made significant improvement in illness perceptions (P<0.001), maladaptive coping (P=0.004), anxiety (P<0.001), depression (P=0.004), and QoL (P<0.001), compared with those at baseline. However, emotion-focused coping and problem-focused coping remained unchanged at week 14 or 30.

Table 2 Infliximab responders: significance of change in questionnaire scores

Meanwhile, 23/82 (28.0%) and 24/82 (29.3%) patients did not achieve clinical remission at weeks 14 and 30, respectively. For these infliximab nonresponders, their psychological characteristics including illness perceptions, coping strategies, anxiety, depression, and QoL achieved no significant improvement after treatment, which are shown in .

Table 3 Infliximab nonresponders: significance of change in questionnaire scores

Discussion

This study aimed to determine the changes of psychological parameters in newly diagnosed CD patients after infliximab treatment. We found that patients who achieved clinical remission had significantly improved illness perceptions, decreased adoption of maladaptive coping strategies, lower levels of anxiety and depression, and better QoL. However, no improvement in psychological parameters was seen in infliximab nonresponders.

As a simple tool to evaluate disease activity for CD patients, HBI decreased significantly after induction treatment in our study. Meanwhile, most patients achieved clinical remission, which was similar to previous research.Citation23Citation27 Infliximab is effective in improving symptoms and alleviating disease severity for CD patients.Citation14

Inflammatory bowel disease (IBD) patients with impaired psychological health and decreased QoL were highly associated with strong belief that IBD would have negative consequences for their life.Citation7 Our study found that with the improvement of disease severity after induction treatment, patient’s illness perceptions improved as well, which was consistent with previous research.Citation28Citation31 However, follow-up study of illness perceptions is little known among IBD patients, which still needs further exploring.

In our study, maladaptive coping decreased significantly after effective treatment for patients achieved clinical remission, while no such changes were seen in emotion-focused coping or problem-focused coping. It could be explained by the previous evidence indicating maladaptive coping is significantly associated with individual’s physical status and psychological status.Citation8,Citation11,Citation13,Citation20,Citation32 As patients become healthier through medical interventions, the need to cope with difficult situations significantly decreases. Nevertheless, a recent longitudinal study evaluating changes of coping strategies in newly diagnosed IBD patients showed different results.Citation20 They found that maladaptive coping did not change with time. In their research, most patients were treated with 5-aminosalicylic acid and immunomodulators, with very few patients treated with corticosteroids and no one used anti-TNF-α agents. However, in our study, all the participants were treated with infliximab, which was thought to be a rapid and effective medication in CD treatment. This might explain why our patients acquired better improvement and used fewer maladaptive coping strategies after treatment.

Patients’ anxiety and depression also decreased significantly after treatment in our cohort. Similar to our results, the study by Calvet et alCitation33 showed that patient’s psychological distress improved greatly and restored to normal levels after 6-month remission, but the research by McCombie et alCitation20 did not find improvement in anxiety or depression after 6-month treatment. Casellas et alCitation34 suggested that the recovery of emotional impairment was delayed compared with the recovery of function on physical and social dimensions. Another interesting finding about psychological issues in our study was that although both anxiety and depression improved significantly after treatment, the extent of improvement in anxiety seemed to be greater. This is probably because patient’s HADS-Anxiety scores were much higher than HADS-Depression scores before treatment in our research, indicating that more CD patients were in anxiety rather than depression.Citation11

One of the primary treatment purposes of chronic diseases is the improvement of patient’s QoL. From the perspective of QoL, an ideal result after treatment should be that patients achieved similar scores in QoL compared with general people. In our study, participants achieving clinical remission reported significant improvement in QoL after treatment, which is in good agreement with previous studies.Citation35Citation42 Moreover, research demonstrated that the early restoration of the QoL after induction treatment in patients with CD was associated with prolonged remission in the future.Citation43 Unconscious little alterations in QoL often reflect individual’s general well-being, sometimes even before the appearance of obvious symptoms. The QoL has shown to be very sensitive to detect early changes of disease activity. Therefore, regular evaluation of QoL is quite meaningful, which can effectively predict the activity of the disease in the long term and discover early signs of disease flares.Citation43Citation45

Our study found that patient’s physical and psychological features including disease severity, illness perceptions, maladaptive coping, anxiety, depression, and QoL changed with time, which is in accordance with the CSM theory.Citation9,Citation10 As the disease activity decreased, patient’s disease cognition and management, psychological status, and QoL improved at the same time, suggesting that disease stimuli, illness perceptions, coping strategies, and illness outcomes had complex interrelationships.Citation8,Citation11,Citation12

There were some limitations in our study. First of all, we used HBI to assess our patient’s disease severity, which mainly represent their clinical symptoms rather than mucosal healing (MH). Research showed that MH was associated with future hospitalization and surgery; thus, it was an important parameter in evaluating patient’s health status.Citation46Citation48 Therefore, evaluation of both clinical and endoscopic disease severities would be a more accurate way of reflecting patient’s disease status. Second, number of flares, changes in laboratory results, and dosage changes in medication were not recorded in our study. These data may reflect patient’s disease status, which could have an influence on patient’s psychological characteristics. Third, all the patients in our study received infliximab treatment, while medications such as 5-aminosalicylic acid, steroids, and immunomodulators were not included. Studies on the comparison of patient’s psychological changes between different treatments could be made in the future. Finally, we re-evaluated patient’s physical and psychological parameters only at weeks 14 and 30. Several studies suggested that effective treatment brought benefits to CD patients both in the short term and up to 1 year, even as long as 4 years.Citation23,Citation39,Citation42,Citation43,Citation49,Citation50 We should make more frequent and longer follow-ups in further studies.

Conclusion

Newly diagnosed CD patients achieving clinical remission after effective infliximab treatment reported improved illness perceptions, maladaptive coping, anxiety, depression, and QoL. Interventions that help reduce patient’s disease activity might also be beneficial to the improvement of their psychological characteristics.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (numbers 81670503 and 81602558) and the Shanghai Committee of Science and Technology Foundation (numbers 16411950408 and 15ZR1426400).

Disclosure

The authors report no conflicts of interest in this work.

References

  • CasellasFArenasJIBaudetJSImpairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter studyInflamm Bowel Dis200511548849615867589
  • VergaraMMontserratACasellasFA new validation of the Spanish Work Productivity and Activity Impairment Questionnaire-Crohn’s disease versionValue Health201114685986121914506
  • SorensenVZOlsenBGBinderVLife prospects and quality of life in patients with Crohn’s diseaseGut19872843823853583066
  • DrossmanDAPatrickDLMitchellCMZagamiEAAppelbaumMIHealth-related quality of life in inflammatory bowel disease. Functional status and patient worries and concernsDig Dis Sci1989349137913862766905
  • IrvineEJQuality of life issues in patients with inflammatory bowel diseaseAm J Gastroenterol1997921218s24s9395348
  • GoodhandJRWahedMMawdsleyJEFarmerADAzizQRamptonDSMood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factorsInflamm Bowel Dis201218122301230922359369
  • van der HaveMBrakenhoffLKvan ErpSJBack/joint pain, illness perceptions and coping are important predictors of quality of life and work productivity in patients with inflammatory bowel disease: a 12-month longitudinal studyJ Crohns Colitis20159327628325547976
  • KnowlesSRCookSITribbickDRelationship between health status, illness perceptions, coping strategies and psychological morbidity: a preliminary study with IBD stoma patientsJ Crohns Colitis2013710e471e47823541738
  • LeventhalHMeyerDNerenzDThe common sense model of illness dangerPetrieKWeinmanJPerceptions of Health and IllnessAmsterdamOPA19801946
  • HaggerMSOrbellSA meta-analytic review of the common-sense model of illness representationsPsychol Health200318141184
  • ZhangMHongLZhangTIllness perceptions and stress: mediators between disease severity and psychological well-being and quality of life among patients with Crohn’s diseasePatient Prefer Adherence2016102387239627920505
  • KnowlesSRWilsonJLConnellWRKammMAPreliminary examination of the relations between disease activity, illness perceptions, coping strategies, and psychological morbidity in Crohn’s disease guided by the common sense model of illnessInflamm Bowel Dis201117122551255721425208
  • KieblesJLDoerflerBKeeferLPreliminary evidence supporting a framework of psychological adjustment to inflammatory bowel diseaseInflamm Bowel Dis201016101685169520155849
  • SiegelCAWhat options do we have for induction therapy for Crohn’s disease?Dig Dis201028354354720926884
  • TravisSPStangeEFLemannMEuropean evidence based consensus on the diagnosis and management of Crohn’s disease: current managementGut200655Suppl 1i16i3516481629
  • HarveyRFBradshawJMA simple index of Crohn’s-disease activityLancet1980181675146102236
  • BestWRBecktelJMSingletonJWKernFJrDevelopment of a Crohn’s disease activity index. National Cooperative Crohn’s Disease StudyGastroenterology19767034394441248701
  • BroadbentEPetrieKJMainJWeinmanJThe brief illness perception questionnaireJ Psychosom Res200660663163716731240
  • CarverCSYou want to measure coping but your protocol’s too long: consider the brief COPEInt J Behav Med1997419210016250744
  • McCombieAMMulderRTGearryRBCoping strategies and psychological outcomes of patients with inflammatory bowel disease in the first 6 months after diagnosisInflamm Bowel Dis201521102272228026099065
  • ZigmondASSnaithRPThe hospital anxiety and depression scaleActa Psychiatr Scand19836763613706880820
  • GuyattGMitchellAIrvineEJA new measure of health status for clinical trials in inflammatory bowel diseaseGastroenterology19899638048102644154
  • RutgeertsPFeaganBGLichtensteinGRComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology2004126240241314762776
  • LonnkvistMHBefritsRLundbergJOInfliximab in clinical routine: experience with Crohn’s disease and biomarkers of inflammation over 5 yearsEur J Gastroenterol Hepatol200921101168117619757522
  • FanRZhongJWangZTEvaluation of “top-down” treatment of early Crohn’s disease by double balloon enteroscopyWorld J Gastroenterol20142039144791448725339835
  • ColombelJFReinischWMantzarisGJRandomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn’s disease – a SONIC post hoc analysisAliment Pharmacol Ther201541873474625728587
  • ChoiCHSongIDKimYHEfficacy and safety of infliximab therapy and predictors of response in Korean patients with Crohn’s disease: a nationwide, multicenter studyYonsei Med J20165761376138527593865
  • TribbickDSalzbergMConnellWDifferences across illness perceptions in inflammatory bowel disease and their relationships to psychological distress and quality of lifeGastroenterol Nurs201740429129928746114
  • DorrianADempsterMAdairPAdjustment to inflammatory bowel disease: the relative influence of illness perceptions and copingInflamm Bowel Dis2009151475518626980
  • RochelleTLFidlerHThe importance of illness perceptions, quality of life and psychological status in patients with ulcerative colitis and Crohn’s diseaseJ Health Psychol201318797298323027780
  • van der HaveMMinderhoudIMKapteinAASubstantial impact of illness perceptions on quality of life in patients with Crohn’s diseaseJ Crohns Colitis201378e292e30123218732
  • KnowlesSRGassCMacraeFIllness perceptions in IBD influence psychological status, sexual health and satisfaction, body image and relational functioning: a preliminary exploration using Structural Equation ModelingJ Crohns Colitis201379e344e35023453888
  • CalvetXGallardoOCoronasRRemission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn’s diseaseInflamm Bowel Dis200612869269616917223
  • CasellasFLópez-VivancosJBadiaXVilasecaJMalageladaJRInfluence of inflammatory bowel disease on different dimensions of quality of lifeEur J Gastroenterol Hepatol200113556757211396538
  • CasellasFLópez-VivancosJBadiaXVilasecaJMalageladaJRImpact of surgery for Crohn’s disease on health-related quality of lifeAm J Gastroenterol200095117718210638579
  • LichtensteinGRBalaMHanCDeWoodyKSchaibleTInfliximab improves quality of life in patients with Crohn’s diseaseInflamm Bowel Dis20028423724312131606
  • CadahiaVGarcia-CarboneroAVivasSInfliximab improves quality of life in the short-term in patients with fistulizing Crohn’s disease in clinical practiceRev Esp Enferm Dig200496369–374747814971999
  • DelaneyCPKiranRPSenagoreAJQuality of life improves within 30 days of surgery for Crohn’s diseaseJ Am Coll Surg2003196571472112742203
  • van BalkomBPSchoonEJStockbruggerRWEffects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn’s diseaseAliment Pharmacol Ther20021661101110712030951
  • ThomsenOOCortotAJewellDBudesonide and mesalazine in active Crohn’s disease: a comparison of the effects on quality of lifeAm J Gastroenterol200297364965311922560
  • IrvineEJGreenbergGRFeaganBGQuality of life rapidly improves with budesonide therapy for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study GroupInflam Bowel Dis200063181187
  • OtleyARGriffithsAMHaleSHealth-related quality of life in the first year after a diagnosis of pediatric inflammatory bowel diseaseInflamm Bowel Dis200612868469116917222
  • Herrera-deGuiseCCasellasFRoblesVNavarroEBorruelNPredictive value of early restoration of quality of life in Crohn’s disease patients receiving antitumor necrosis factor agentsJ Gastroenterol Hepatol201530228629125302652
  • MittermaierCDejacoCWaldhoerTImpact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up studyPsychosom Med2004661798414747641
  • CamaraRJJuilleratPPittetVQuality of life: a potentially useful measure to indicate subclinical flares in Crohn diseaseIntern Med J2012427e145e15121395959
  • RutgeertsPDiamondRHBalaMScheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s diseaseGastrointest Endosc2006633433442 quiz 6416500392
  • FroslieKFJahnsenJMoumBAVatnMHMucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohortGastroenterology2007133241242217681162
  • SchnitzlerFFidderHFerranteMMucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s diseaseInflamm Bowel Dis20091591295130119340881
  • HanauerSBFeaganBGLichtensteinGRMaintenance inflix-imab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
  • CasellasFRodrigoLNiñoPPantigaCRiestraSMalageladaJRSustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 yearsInflamm Bowel Dis200713111395140017567874